Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

CoreLogic Q4 Net Loss Narrows; Reconfirms FY12 Guidance - Quick Facts

RELATED NEWS
Trade CLGX now with 

CoreLogic, Inc. (CLGX: Quote) reported that its fourth-quarter net loss attributable to the company narrowed to $14.14 million or $0.13 per share, from $27.74 million or $0.24 per share in the same quarter last year.

Operating revenue for the quarter rose to $345.40 million from $315.37 million in the prior year quarter. Analysts polled by Thomson Reuters expected the company to report revenues of $330.68 million for the quarter. Analysts' estimates typically exclude special items.

The company reconfirmed its guidance for 2012. The company still expects adjusted earnings in a range of $0.95 to $1.05 and adjusted revenue of $1.425 billion to $1.475 billion for fiscal year 2012. Analysts expect the company to report earnings of $0.95 per share on revenues of $1.47 billion for fiscal 2012.

Click here to receive FREE breaking news email alerts for CoreLogic Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Colorado based doctor Dilip Joseph, who was kidnapped by the Taliban discusses his ordeal in detail in a book published by Amazon on Tuesday. Extending the rebound seen over the course of the previous session, stocks moved sharply higher during trading on Friday. The gains on the day partly offset the recent sell-off on Wall Street, although the major averages remain well off their mid-September highs. While the Ebola outbreak in the U.S. has thus far been limited to just three people, the results of a new CBS News poll suggest that news of the disease has contributed to a sharp drop in public confidence in the Centers for Disease Control and Prevention.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.